Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 10/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3233725 | 0.91 | ALDH1A1 (0.39) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL16369620 | 0.91 | ALDH1A1 (0.40) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL3242812 | 0.91 | ALDH1A1 (0.40) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL3234068 | 0.88 | ACHE (0.46) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL3230256 | 0.86 | HDAC3 (0.38) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL2122406 | 0.86 | HDAC1 (0.42) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL3236792 | 0.85 | HDAC1 (0.42) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL3242809 | 0.84 | HDAC3 (0.36) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL3230242 | 0.81 | HDAC1 (0.43) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL3234078 | 0.80 | HPGD (0.43) | HDAC3HDAC1HDAC2HDAC10HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957225-B2 | Treatment of friedreich's ataxia using histone deacetylase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-01 | — | — | US | disclosed |
| EP-3006424-A1 | HISTONE DEACETYLASE INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISEASES | The Scripps Research Institute (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-1951656-B1 | HISTONE DEACETYLASE INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISEASES | SCRIPPS RESEARCH INST (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150080472-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE | 2015-03-19 | — | — | US | disclosed |
| US-8835502-B2 | Treatment of friedreich's ataxia using histone deacetylase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-09-16 | — | — | US | disclosed |
| US-20130210918-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-15 | — | — | US | disclosed |
| US-20110021562-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | THE SCRIPPS RESEARCH INSTUTE (US) | 2011-01-27 | — | — | US | disclosed |
| US-20070219244-A1 | Histone deacetylase inhibitors as therapeutics for neurological diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021562-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC4, HDAC6 | HDAC3 11/4885HDAC1 1/4885HDAC2 5/4885 |
| US-20130210918-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC4, HDAC6 | HDAC3 11/4885HDAC1 1/4885HDAC2 5/4885 |
| US-20150080472-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC4, HDAC6 | HDAC3 11/4885HDAC1 1/4885HDAC2 5/4885 |
| US-20070219244-A1 | Histone deacetylase inhibitors as therapeutics for neurological diseases | HDAC5, HDAC1, HDAC6 | HDAC3 9/4885HDAC1 2/4885HDAC2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.